Cirrhosis of liver

Related records

Broader conditions (7)

• Digestive system disorder
• Disease
• Disease by body system or component
• Endocrine system disorder
• Hepatobiliary disorder
• Human disease
• Liver disorder

Narrower conditions (11)

• Alcoholic liver cirrhosis
• Cirrhosis, familial
• Cirrhosis, familial, with antigenemia
• Hepatitis C induced liver cirrhosis
• Isolated congenital hepatic fibrosis
• Primary biliary cholangitis
• Primary biliary cholangitis 1
• Primary biliary cholangitis 2
• Primary biliary cholangitis 3
• Primary biliary cholangitis 4
• Primary biliary cholangitis 5

Trials (2,494)

• "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
• "Early TIPS" Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices
• "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
• "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
• "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
• 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
• 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
• ¹³C-Methacetin Breath Test (MBT) Methodology Study
• 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
• 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid in Cirrhosis With Sepsis Induced Hypotension
• 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
• 3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
• 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8
• 3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
• 3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
• 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
• 4beta-hydroxycholesterol in Cirrhosis
• 4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis
• 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C
• A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites

Approved drugs (6)

• Ethacrynic acid
• Furosemide
• Hydrochlorothiazide
• Ribavirin
• Spironolactone
• Triamterene

Drugs in development (76)

• Albumin human Phase 3
• Alcohol Phase 2
• Allopurinol Phase 2
• Amino acids Phase 3
• Apixaban Phase 2
• Atorvastatin Phase 2
• Bemiparin Phase 3
• Bifendate Phase 1
• Bosentan Phase 2
• Calcium carbonate Phase 3
• Colchicine Phase 1
• Conivaptan Phase 2
• Cyclobenzaprine Phase 3
• Dapagliflozin Phase 2
• Dexamethasone Phase 3
• Dextran 40 Phase 2
• Edoxaban Phase 2
• Eltrombopag Phase 1
• Emricasan Phase 2
• Enoxaparin sodium Phase 2

Other linked drugs (8)

• Fentanyl
• Levopropranolol
• Midodrine
• Naltrexone
• Resmetirom
• Selenium
• Semaglutide
• Tacrolimus